Johnson & Johnson stock gains on earnings and guidance

Johnson & Johnson (US4781601046) stock traded at USD 275.63 on September 3, 2026, close to its 52-week high of USD 281.07. MarketBeat said the company recently topped quarterly earnings and revenue expectations and lifted FY 2026 EPS guidance to USD 11.60 to USD 11.75.

Earnings set the pace

According to MarketBeat, the group reported USD 2.90 in quarterly EPS on July 15, 2026, versus USD 2.84 expected, and revenue of USD 25.31 billion versus USD 25.06 billion expected. Revenue rose 6.6 percent from the prior year quarter, while EPS improved from USD 2.77 a year earlier.

The same source said the company now guides for USD 11.60 to USD 11.75 in FY 2026 EPS, while analysts on average expect USD 11.61. That puts the stock near the top of its range after a 2026 move that already reached USD 275.63 on September 3, 2026.

Consensus stays supportive

MarketBeat also reported a consensus rating of Moderate Buy and an average price target of USD 272.83, with UBS starting coverage at USD 320 and Citi and TD Cowen also lifting targets. For investors, the gap between the USD 275.63 share price and the USD 272.83 average target is now part of the debate.

Dividend and valuation

The company declared a quarterly dividend of USD 1.34 a share, equal to USD 5.36 annualized and a 1.9 percent yield. MarketBeat put the market capitalization at USD 664.25 billion and the price to earnings ratio at 31.94.

Drug pipeline remains key

MarketScreener showed Johnson & Johnson trading at EUR 239.45 on Tradegate on September 4, 2026, with a 1st Jan change of 2.48 percent and a 5-day change of 0.80 percent. The same page highlighted sector consensus around the pharmaceutical group and pointed to a UBS note on the drug pipeline supporting the growth outlook.

Stock near its high

Johnson & Johnson stock was listed at USD 275.63 on September 3, 2026, against a 52-week range of USD 173.33 to USD 281.07. The share price sits within 2.0 percent of the high and the stock trades with the market still focused on earnings quality and FY 2026 guidance.